Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis

Open access
Gando, Satoshi, Saitoh, Daizoh, Ishikura, Hiroyasu, Ueyama, Masashi, Otomo, Yasuhiro, Oda, Shigeto, Kushimoto, Shigeki, Tanjoh, Katsuhisa, Mayumi, Toshihiko, Ikeda, Toshiaki, Iba, Toshiaki, Eguchi, Yutaka, Okamoto, Kohji, Ogura, Hiroshi, Koseki, Kazuhide, Sakamoto, Yuichiro, Takayama, Yasuhiro, Shirai, Kunihiro, Takasu, Osamu, Inoue, Yoshiaki, Mashiko, Kunihiro, Tsubota, Takaya, Endo, Shigeatsu, Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT)·2013·Critical Care

Abstract

Introduction: To test the hypothesis that the administration of antithrombin concentrate improves disseminated intravascular coagulation (DIC), resulting in recovery from DIC and better outcomes in patients with sepsis, we conducted a prospective, randomized controlled multicenter trial at 13 critical care centers in tertiary care hospitals. Methods: We enrolled 60 DIC patients with sepsis and antithrombin levels of 50 to 80% in this study. The participating patients were randomly assigned to an antithrombin arm receiving antithrombin at a dose of 30 IU/kg per day for three days or a control arm treated with no intervention. The primary efficacy end point was recovery from DIC on day 3. The analysis was conducted with an intention-to-treat approach. DIC was diagnosed according to the Japanese Association for Acute Medicine (JAAM) scoring system. The systemic inflammatory response syndrome (SIRS) score, platelet count and global markers of coagulation and fibrinolysis were measured on day 0 and day 3. Results: Antithrombin treatment resulted in significantly decreased DIC scores and better recovery rates from DIC compared with those observed in the control group on day 3. The incidence of minor bleeding complications did not increase, and no major bleeding related to antithrombin treatment was observed. The platelet count significantly increased; however, antithrombin did not influence the sequential organ failure assessment (SOFA) score or markers of coagulation and fibrinolysis on day 3. Conclusions: Moderate doses of antithrombin improve DIC scores, thereby increasing the recovery rate from DIC without any risk of bleeding in DIC patients with sepsis. Trial registration: UMIN Clinical Trials Registry (UMIN-CTR) UMIN000000882

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/cc13163

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 185

Metadata

Authors
Gando, S., Saitoh, D., Ishikura, H., Ueyama, M., Otomo, Y., Oda, S., Kushimoto, S., Tanjoh, K., Mayumi, T., Ikeda, T., Iba, T., Eguchi, Y., Okamoto, K., Ogura, H., Koseki, K., Sakamoto, Y., Takayama, Y., Shirai, K., Takasu, O., Inoue, Y., Mashiko, K., Tsubota, T., Endo, S., & Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT)
Venue
Critical Care
Published
2013-12-16
Volume
17
Issue
6
Pages
R297-R297
ISSN
1364-8535 (ISSN-L)
OpenAlex
W2078586062
Cited by
185
References
3
FWCI
8.00
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. https://app.cochat.ai/papers/10.1186/cc13163
The paper
Gando, S., Saitoh, D., Ishikura, H., Ueyama, M., Otomo, Y., Oda, S., Kushimoto, S., Tanjoh, K., Mayumi, T., Ikeda, T., Iba, T., Eguchi, Y., Okamoto, K., Ogura, H., Koseki, K., Sakamoto, Y., Takayama, Y., Shirai, K., Takasu, O., . . . Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). (2013). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Critical Care. https://doi.org/10.1186/cc13163

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.